Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New research analyzing Merck & Co.'s Janumet has revealed that it provides substantial reductions in blood sugar levels in type 2 diabetes patients.
Subscribe to our email newsletter
Janumet is an investigational combination therapy of sitagliptin phosphate plus metformin. Janumet is designed to provide an additional treatment option for patients who need more than one oral agent to help control their blood sugar.
In the study, patients had an average blood glucose level of 287 milligrams per milliliter two hours after eating, and 197 milligrams per milliliter on an empty stomach.
“Typically, oral medications for type 2 diabetes principally either reduce post-meal glucose levels or reduce fasting blood glucose levels. These study data are important because they showed substantial reductions in both measures of blood glucose levels,” said John Amatruda, vice president, clinical research, Merck & Co.
Janumet is currently under review by the FDA and Merck expects action on the new drug application by the end of March 2007. The company said it is also moving forward as planned with regulatory filings in countries outside the US.